Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT06813573
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • blood sampling — BIOLOGICAL
    A maximum of 4 tubes of 10ml will be collected: at baseline (before cycle 1), before each cycle (from 2 to 6 included), at the end of the treatment, and in case of relapse during follow-up period

Study Details

The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.

Key Dates

First listed
Feb 7, 2025
Start date
Sep 30, 2024
Status verified
Feb 2025
Primary completion
Oct 31, 2028
Completion
Oct 31, 2029

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Patients receiving first line of treatment with a RCHOP 21 regimen
    All patients will receive first line of treatment with a RCHOP 21 regimen

Primary Outcome Measure

Prospective quantitative analysis of the level of circulating nucleosomes at baseline and during treatment in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) [ Time Frame: From enrollment to the end of the study (24 months of follow-up from beginning of treatment for each patient) ]

Central Contacts

Related Studies